Sigmoid Biotechnologies - Liquid / Emulsion Drug Delivery System

Founded by former Elan and Ntera executives, Sigmoid Biotechnologies is a speciality pharmaceutical company engaged in the development of pharmaceutical products based on its novel oral drug delivery technologies.

Sigmoid is focused on developing Liquid / Emulsion Drug Delivery System (LEDDS®), a proprietary drug delivery technology. This system will improve the effectiveness, safety and convenience of existing drugs and enhance next-generation drug delivery. LEDDS is uniquely positioned to enable the controlled release of orally administered drugs in liquid form, a process previously only suitable to drugs in powder form, and thus it presents a commercial opportunity in drug delivery.

From drug delivery to product enhancement, Sigmoid is your answer to poor or insoluble compounds.

CLINICAL BENEFITS OF LEDDS

The LEDDS ensures delivery of a liquid / emulsion drug to the optimal site of action. The system encourages rapid onset of action and ensures the controlled and sustained release of liquid or emulsion drugs.

The drug is delivered so as to achieve maximum absorption and the active ingredient is protected from the harsh gastric and intestinal environments.

KEY LEDDS PRODUCT DEVELOPMENT BENEFITS

The protection from light and oxidation the LEDDS offers the active ingredient is one of the key benefits of the system as it ensures enhanced stability for the product.

LEDDS' reduced attrition broadens the development stage pipelines, and permit patent extension leads to product life-cycle extension. The system also introduces novel drug combinations to extend applications.

POTENTIAL COMMERCIAL OPPORTUNITIES

The LEDDS delivers one or more actives in the same dosage form at predetermined rate(s) to enhance disease management and patient compliance. By preventing high local concentration of the actives to the gastrointestinal mucosa, the LEDDS can deliver actives that irritate the gastrointestinal mucosa.

Taste masking of therapeutic agents is also inherent with the liquid / emulsion drug delivery technology, and the ease of oral administration make the system ideal for the geriatric and paediatric markets.

LEADERS IN THE DRUG DELIVERY FIELD

Sigmoid is an innovative speciality pharmaceutical company that meets the challenges of the pharmaceutical and biotechnology industries using its proprietary technologies.

The company has been at the forefront of significant developments in the drug delivery field. Sigmoid has recently been awarded two important accolades for innovation in the area. In October 2005, Sigmoid were awarded the Science Foundation Ireland (SFI) Industry Research Grant to generate innovative and powerful drug delivery concepts, and in December 2005, Sigmoid won the SeedCorn Business Competition for entrepreneurs in Ireland.